影响持续使用内注射治疗勃起功能障碍的因素:回顾性分析
Braian Rene Ledesma1, Jason Codrington1, David Velasquez1
1Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
The world journal of men's health
|September 30, 2024
概括
年龄较大,先前的前列腺癌治疗,以及西班牙语偏好与对勃起功能障碍的洞内注射的坚持程度较低有关. 了解这些因素可以改善患者的咨询和治疗选择.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 男人的健康 男人的健康
- 药物治疗 药物治疗
背景情况:
- 内腔鼻内注射是勃起功能障碍 (ED) 的关键治疗方法.
- 患者的坚持对于成功的ED治疗结果至关重要.
- 影响内注射的因素在很大程度上仍未确定.
研究的目的:
- 确定与患者遵守和继续治疗相关的关键因素,以在男性内内注射ED.
- 分析影响内注射治疗持续时间的人口和临床变量.
主要方法:
- 对4072名被处方内腔注射的患者 (2017-2022) 的回顾性分析.
- 使用处方补充数据计算治疗的持续时间.
- 雇佣的考克斯比例风险回归来评估治疗中止的预测因素.
主要成果:
- 年龄增加显著预测停药 (HR为每年1.007,p<0.001).
- 西班牙语偏好与更高的戒断率有关 (HR 1.163,p=0.004).
- 前列腺癌治疗史将治疗时间平均减少80天 (p=0.002).
结论:
- 年龄较大,先前的前列腺癌治疗和西班牙语偏好与减少ED内腔内注射治疗的延续有关.
- 这些发现凸显了为量身定制的患者选择和咨询策略的需要.
- 了解这些因素可以优化治疗坚持和男性勃起功能障碍的结果.
相关概念视频
Disorders of the Male Reproductive System
351
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
351
Infertility in Males
253
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
253
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
132
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
132


